2026 ASCO® ANNUAL MEETING

NAPISTAR 1-01: Results of phase 1 dose escalation of monotherapy with TUB-040, a novel NaPi2b-targeting exatecan ADC, in patients (pts) with platinum-resistant ovarian cancer (PROC)

Toon Van Gorp, Jalid Sehouli, Debra L. Richardson, Rebecca Kristeleit, Shiraj Sen, Juergen Wolf, Valentina Boni, Alexander Spira, Alexander Starodub, Björn Hock, Charles S. Fuchs, Yariv Houvras, Ines Vasconcelos, Antonio Gonzalez-Martin.

Toon Van Gorp
Leuven Cancer Institute, Leuven, Belgium

Key takeaways

- **NaPi2b** is sodium-phosphate transporter which is **expressed in > 95%** of **high grade serous ovarian cancer**
- In the cohorts of **1.67-3.3 mg/kg TUB-040** delivers **deep and durable responses** with **minimal grade ≥3 hematological toxicity**
- **Manageable adverse event profile with low discontinuation rates** due to a treatment emergent adverse event
- **Unconfirmed and confirmed ORR** of **67%** (95% CI 52.0%, 80.5%) and **61%** (95% CI 45.4%, 74.9%); respectively in the 1.67-3.3 mg/kg cohorts
- In the overall population, clinically meaningful **mPFS of 11.0 months,** with a **response duration > 6 months in 79%**
- **These encouraging results in PROC support rapid development of TUB-040 in non biomarker restricted ovarian cancer population**

TUB-040 demonstrated significant durable efficacy and low rates of haematological toxicity, in heavily pre-treated PROC patients

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

N=66 evaluable patients who had at least 1 RECIST response assessment across doses from 0.5 – 5.3 mg/kg. There were no responses observed at doses below 1.67 mg/kg. Responses of PR/CR per RECIST at a minimum of 1 post-baseline assessment. Efficacy data in patients treated at 3.3 mg/kg continue to mature. CR, complete response; DCR, disease control rate; PR, partial response; SD, stable disease. Data Cut off: 05 April 2026.

Background

- Platinum-resistant ovarian cancer patients have an overall survival of 12-16 months. New, efficacious and well tolerated therapeutic options are needed
- NaPi2b is a rapidly internalizing sodium-phosphate transporter which is highly overexpressed in ovarian cancer
- TUB-040 is optimized to maximize efficacy and tolerability with innovative ADC design elements:
  - Fc-silencing to minimize off target toxicities
  - P5 mAB linkage with stable DAR; no premature payload loss and enhanced hydrophilicity
  - Peptide-cleavable linker for efficient intracellular release
  - Clinically validated, exatecan payload (TOP-1) with bystander activity

DESIGN ELEMENTS OF TUB-040



αNaPi2b - P5 mAb linkage - peptide-cleavable release - Exatecan

Here we report the updated safety and efficacy data from the dose escalation phase of the NAPISTAR 1-01 study in PROC, with a focus on dose levels 1.67-3.3 mg/kg

1. Richardson et al., 2023. (DOI:10.1001/jamaoncol.2023.0197)
2. Lin et al., 2015. (DOI:10.1158/1078-0432.CCR-14-3383)
3. Vogl et al., 2025. (DOI:10.1158/1535-7163.MCT-25-0254)
4. Taylor et al., 2024. (DOI:10.1182/blood.2024024442)
5. Wei et al., 2025. (DOI:10.1158/0008-5472.CAN-24)
6. Schmitt et al., 2024. (DOI:10.1158/1535-7163.MCT-23-0359)
7. Kasper et al., 2019. (DOI:10.1002/anie.201904193)
8. O'Reilly et al., 2004. (DOI:10.1200/jco.2004.22.90140.4006)
9. Khera et al., 2022. (DOI:10.1158/1535-7163.MCT-21-0580)
10. Mitsui et al., 1995. (DOI:0.1111/j.1349-7006.1995.tb02468)
11. Hsiang et al., 1985. (DOI:10.1016/S0021-9258(17)38654-4)

Data Cut off: 05April 2026. ADC, antibody drug conjugate; DAR8, drug-to-antibody ratio 8; Fc, fragment crystallizable; mAb, monoclonal antibody; IgG1, immunoglobulin NaPi2b, sodium-dependent phosphate transporter protein 2B; P5, phosphonamidate; TOPO-I, type 1 topoisomerase.

NAPISTAR 1-01: study design

A multicenter, FIH dose escalation and optimization Phase I/IIa Study (NCT06303505), investigating the NaPi2b ADC TUB-040 in PROC*

PHASE I

Dose Escalation



Study design: ATD followed by BOIN

PHASE IIa

Dose Optimization

- 2.1 mg/kg
- 2.5 mg/kg
- 3.3 mg/kg

Key Eligibility Criteria

- Histologically confirmed, platinum resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer
- A maximum of 5 platinum-based and 2 non-platinum prior lines of therapy
- ECOG 0-1
- No prior treatment with an ADC containing a TOPO-I inhibitor payload
- No biomarker selection based on NaPi2b expression

Objectives and Endpoints

- Safety and tolerability
- Determination of MTD
- ORR per RECIST 1.1, DCR, DoR, PFS and OS
- PK parameters of TUB-040
- Immunogenicity
- Quality of life

NAPISTAR 1-01 also includes an NSCLC arm, which is currently being explored independently from the PROC arm. Cut off: 05April 2026.
ADC, antibody-drug conjugate; ATD, accelerated titration dosing; BOIN, Bayesian optimal interval; DCR, disease control rate; DoR, duration of response; FIH, first-in-human; MTD, maximum tolerated dose; NaPi2b, sodium-dependent phosphate transporter protein 2B; ORR, overall response rate; OS, overall survival;; PFS, progression-free survival; PK, pharmacokinetics; PROC, platinum-resistant ovarian cancer.

NAPISTAR 1-01: patient demographics and safety summary

Baseline characteristic	Overall (N=67)
Age, years Median (range)	62.0 (34.0 - 81.0)
ECOG PS, n (%) 0 1	 37 (55.2) 30 (44.8)
Time from first diagnosis, years Median (range)	4.3 (0.9 -16.7)
Prior lines of therapy, n Median (range)	 4 (1-7)
Prior bevacizumab, n (%)	56 (83.6)
Prior PARP inhibitor, n (%)	51 (76.1)
Prior IO therapy, n (%)	16 (23.9)
Prior mirvetuximab soravtansine, n (%)	10 (14.9)

Safety Summary	1.67-3.3 mg/kg (n=46)	0.5-5.3 mg/kg* (n=67)
Any TEAE[1], n (%) Grade >=3	46 (100) 19 (41)	67 (100) 36 (54)
Any Serious TEAE, n (%)	12 (26)	20 (30)
Dose modifications Dose reductions due to TEAE Treatment discontinuation due to TEAE	 12 (26) 0	 26 (39) 2 (3)
Nausea (all grades) Grade ≥ 3	36 (78) 2 (4)	51 (76) 2 (3)
Fatigue (all grades) Grade ≥ 3	26(57) 0	40 (60) 0
Neutropenia (all grades) Grade ≥ 3	21 (46) 13 (28)	36 (54) 28 (42)
Anemia (all grades) Grade ≥ 3	18 (39) 8 (17)	32 (48) 18 (27)
Thrombocytopenia (all grades) Grade ≥ 3	7 (15) 2 (4)	20 (30) 12 (18)
Pneumonitis (Grade 1) Grade ≥ 3	3 (7) 0	5 (8) 0

- **Heavily pre-treated patient population with a median of 4 prior lines of therapy; the majority of patients exposed to prior bevacizumab and/or a PARP inhibitor**
- **Manageable adverse event profile with low discontinuations due to treatment related AEs**

All subjects with a NaPi2b IHC evaluation at the time of the DCO are included. Data Cut off: 05 April 2026. ECOG, Eastern Cooperative Oncology Group; NaPi2b, sodium-dependent phosphate transporter protein 2B; PARP, poly ADP ribose polymerase; PS, performance score.

Efficacy across a wide therapeutic range with complete responses



N=66 evaluable patients who had at least 1 RECIST response assessment across doses from 0.5 – 5.3 mg/kg. There were no responses observed at doses below 1.67 mg/kg. Responses of PR/CR per RECIST at a minimum of 1 post-baseline assessment. CR, complete response; PR, partial response; SD, stable disease. Data Cut off: 05April 2026.

Consistent responses across multiple subgroups – all dose levels

Subgroup	Responders	Total (N)	ORR (95% CI)
Number of prior therapy lines			
< 4	14	28	50.0 (30.6 to 69.4)
≥ 4	25	39	64.1 (47.2 to 78.8)
Prior Exposure to Bevacizumab			
Yes	32	56	57.1 (43.2 to 70.3)
No	7	11	63.6 (30.8 to 89.1)
Prior Exposure to PARP inhibitors			
Yes	31	51	60.8 (46.1 to 74.2)
No	8	16	50.0 (24.7 to 75.3)
Prior Exposure to Immunotherapy			
Yes	10	16	62.5 (35.4 to 84.8)
No	29	51	56.9 (42.2 to 70.7)
Prior Exposure to Mirvetuximab			
Yes	5	10	50.0 (18.7 to 81.3)
No	34	57	59.6 (45.8 to 72.4)
Napi2B IHC			
High	33	56	58.9 (45.0 to 71.9)
Low	4	7	57.1 (18.4 to 90.1)
Missing	2	4	50.0 (6.8 to 93.2)



Data cut-off 05 April 2026.

Clinically meaningful progression free survival – all dose levels



mPFS of 11 months with 71% and 50% progression free at 6 months and 12 months, respectively

Data cut-off 05 April 2026 . Median duration of follow-up 12 months.

Clinically meaningful and durable responses – all dose levels



mDOR not reached with 79% and 57% of responders with a duration > 6 months and > 12 months, respectively

Data cut-off 05 April 2026. Median duration of follow-up 8.7 months.

Clinically meaningful responses across doses 1.67-3.3 mg/kg

67% uORR (95% CI 50.2,80.5)
61% cORR (95% CI 45.4,74.9)



Consistent durable high response rate and deep responses across the dose levels of 1.67-3.3 mg/kg with 74% of responders ongoing treatment

N=66 evaluable patients who had at least 1 RECIST response assessment across doses from 0.5 – 5.3 mg/kg. There were no responses observed at doses below 1.67 mg/kg.
Responses of PR/CR per RECIST at a minimum of 1 post-baseline assessment. . Efficacy data in patients treated at 3.3 mg/kg continue to mature. CR, complete response; PR, partial response; SD, stable disease. Data Cut off: 05 April 2026.

TUB-040 is well tolerated across doses 1.67-3.3 mg/kg



- TUB-040 demonstrates a tolerable safety profile in PROC with the majority of events being low grade
- Hematologic toxicity was predominately low-grade and manageable at doses of 1.67 – 3.3 mg/kg
- No clinically relevant bleeding, pneumonitis, ocular toxicity, stomatitis, or neuropathy

Data cut-off 05 April 2026.

Limited grade ≥3 hematological toxicity across doses 1.67-3.3 mg/kg

Blood & lymphatic system disorders	1.67 mg/kg N=10 n (%)	2.1 mg/kg N=12 n (%)	2.5 mg/kg N=12 n (%)	3.3 mg/kg N=12 n (%)	Total N=46 n (%)
Anaemia	0 (0%)	0 (0%)	3 (25.0%)	5 (41.7%)	8 (17.4%)
Neutropenia	0 (0%)	2 (16.7%)	5 (41.7%)	6 (50.0%)	13 (28.2%)
Thrombocytopenia	0 (0%)	0 (0%)	1 (8.3%)	1 (8.3%)	2 (4.3%)
Febrile neutropenia	0 (0%)	0 (0%)	0 (0%)	1 (8.3%)	1 (2.2%)
Leukopenia	0 (0%)	0 (0%)	1 (8.3%)	0 (0%)	1 (2.2%)

Prophylactic/supportive therapy with G-CSF was not mandated per protocol but could be used per investigator discretion/institutional guidance after cycle 1

Data cut-off 05 April 2026.

Conclusions

- **NaPi2b** is sodium-phosphate transporter which is **expressed in > 95%** of **high grade serous ovarian cancer**
- In the cohorts of **1.67-3.3 mg/kg TUB-040** delivers **deep and durable responses** with **minimal grade ≥3 hematological toxicity**
- **Manageable adverse event profile with low discontinuation rates** due to a treatment emergent adverse event
- **Unconfirmed and confirmed ORR** of **67%** (95% CI 52.0%, 80.5%) and **61%** (95% CI 45.4%, 74.9%); respectively in the 1.67-3.3 mg/kg cohorts
- In the overall population, clinically meaningful **mPFS of 11.0 months,** with a **response duration > 6 months in 79%**
- **These encouraging results in PROC support rapid development of TUB-040 in non biomarker restricted ovarian cancer population**

TUB-040 demonstrated significant durable efficacy and low rates of haematological toxicity, in heavily pre-treated PROC patients

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

N=66 evaluable patients who had at least 1 RECIST response assessment across doses from 0.5 – 5.3 mg/kg. There were no responses observed at doses below 1.67 mg/kg. Responses of PR/CR per RECIST at a minimum of 1 post-baseline assessment. Efficacy data in patients treated at 3.3 mg/kg continue to mature. CR, complete response; DCR, disease control rate; PR, partial response; SD, stable disease. Data Cut off: 05 April 2026.